FRI0128 A Phase III Randomised, Double-Blind Clinical Study Comparing SB4, An Etanercept Biosimilar, With Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-Week Results)

Abstract

BackgroundSB4 is a biologic agent developed as a biosimilar of the etanercept reference product (ETN). Etanercept is approved for treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, axial...